{
“subject”: “Ribociclib API (UBX11) – GMP Supply, DMF/CEP Support & Strategic Partnership”,
“content”: “
I noticed that USV Private Limited has a strong portfolio in the diabetic and cardiac segments, more than 100 global product approvals, and a growing small-molecule API development network. As you continue to expand your oncology pipeline, I wanted to introduce a high-value opportunity around Ribociclib (UBX11), a CDK4/6 inhibitor with significant market potential.
Ribociclib is a strategic program for us. The originator product Kisqali generated approximately USD 4.78 billion in global sales during 2025, with peak expectations now exceeding USD 10 billion. With core composition patents expected around 2029 in multiple markets, this is the right time to begin development, registration, and supply chain planning. We are positioned to support your team with GMP-compliant Ribociclib API, robust DMF/CEP/ASMF documentation, stringent nitrosamine controls, and validated commercial-scale manufacturing.
Our company, Unibest Industrial Co., Ltd., specializes in API and intermediate exports from China. We combine reliable production capacity, international registration expertise, and responsive supply chains. For USV, this can mean a cost-efficient, well-documented source to support your upcoming formulation projects or tender opportunities. I would welcome the chance to share our technical dossier, regulatory packages, and indicative pricing, and to discuss a potential supply agreement with your procurement and technical teams.
Would it be possible to arrange a call or virtual meeting in the coming weeks to review your development timelines and registration requirements in more detail? If helpful, we can also provide reference samples or a small quantity for feasibility testing.
For more product details, please visit: Chemical Compositions
For more biological ingredients, please visit: Biological Ingredients
”
}
